GlaxoSmithKline PLC GSK completes partial sale of Aspen (3649H)
13 March 2015 - 6:00PM
UK Regulatory
TIDMGSK
RNS Number : 3649H
GlaxoSmithKline PLC
13 March 2015
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL
ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN OR
THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
13 March 2015, London UK - LSE announcement
GSK completes partial sale of Aspen Pharmacare Holdings Ltd
shares
Further to the announcement by GSK on 12 March 2015, GSK has
agreed to the sale of 28.2 million ordinary shares in Aspen
Pharmacare Holdings Ltd ("Aspen") at a price of ZAR 372 per share
(the "Placing Shares"), raising gross proceeds of approximately ZAR
10.5 billion.
Following settlement of the sale, GSK will hold 28.2 million
ordinary shares in Aspen, representing approximately 6.2% of the
issued share capital. GSK has undertaken not to dispose of any
further shares in Aspen for a period of 180 days following
completion, subject to certain limited exceptions.
The gross proceeds of thetransaction are equivalent to GBP 574
million at the prevailing exchange rate on 12 March 2015. Proceeds
from the transaction will be used for general corporate purposes.
The net profit on disposal will not be included in core operating
profit and core EPS in 2015 and it is expected that GSK will no
longer account for Aspen as an associate going forward.
GSK - one of the world's leading research-based pharmaceutical
and healthcare companies - is committed to improving the quality of
human life by enabling people to do more, feel better and live
longer. For further information please visit www.gsk.com.
GSK enquiries:
UK Media enquiries: David Mawdsley +44 (0) 20 8047 (London)
5502
Simon Steel +44 (0) 20 8047 (London)
5502
David Daley +44 (0) 20 8047 (London)
5502
Catherine Hartley +44 (0) 20 8047 (London)
5502
Sarah Spencer +44 (0) 20 8047 (London)
5502
Claire Brough +44 (0) 20 8047 (London)
5502
Analyst/Investor Ziba Shamsi +44 (0) 20 8047 (London)
enquiries: 5543
Gary Davies +44 (0) 20 8047 (London)
5503
James Dodwell +44 (0) 20 8047 (London)
2406
Cautionary statement regarding forward-looking statements
This announcement does not constitute a prospectus or an offer
or invitation to purchase securities.
This announcement is only addressed to, and directed at, persons
in member states of the European Economic Area ("EEA") who are
"qualified investors" within the meaning of Article 2(1)(e)
of the Prospectus Directive (Directive 2003/71/EC) as amended
by the 2010 PD Amending Directive (Directive 2010/73/EU), as
and to the extent implemented in the relevant EEA member state,
and any relevant implementing measure in the relevant member
state.
In addition, in the United Kingdom, this announcement is not
being distributed, nor has it been approved for the purposes
of Section 21 of the Financial Services and Markets Act 2000
("FSMA"), by a person authorised under FSMA and is directed
only at persons (i) who are persons having professional experience
in matters relating to investments who fall within the definition
of "investment professionals" in Article 19(5) of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005,
as amended (the "Order"), or (ii) persons who are high net worth
entities falling within Article 49(2)(a) to (d) of the Order,
or (iii) other persons to whom it may lawfully be communicated
("relevant persons"). Under no circumstances should persons
who are not relevant persons rely or act upon the contents of
this announcement. Any investment or investment activity to
which this announcement relates in the United Kingdom is available
only to, and will be engaged only with, relevant persons.
This announcement is not an offer for sale of securities in
the United States. Securities may not be offered or sold in
the United States absent registration with the United States
Securities and Exchange Commission or an exemption from registration
under the U.S. Securities Act of 1933, as amended. GSK does
not intend to register any part of the offering in the United
States or to conduct a public offering in the United States
of the shares to which this announcement relates.
The Offering and the distribution of this announcement do not,
nor are they intended to, constitute an offer for the sale of
or subscription for, or the solicitation of an offer to buy
and subscribe for, shares to the public as defined in the South
African Companies Act, No 71 of 2008 (as amended or otherwise)
(the "South African Act") and will not be distributed to any
person in South Africa in any manner which could be construed
as an offer to the public in terms of the South African Act.
The Offering and the distribution of this announcement do not,
nor are they intended to, constitute a prospectus prepared and
registered under the South African Act.
The Offering and the distribution of this announcement and other
information in connection with the Offering in certain jurisdictions
may be restricted by law. No action has been taken that would
permit the Offering or distribution of this announcement in
any jurisdiction where action for such purpose is required.
Persons into whose possession any document or other information
referred to herein comes should inform themselves about and
observe any such restriction. Any failure to comply with these
restrictions may constitute a violation of the securities laws
of any such jurisdiction.
Citigroup Global Markets Limited and UBS Limited, which are
authorised and regulated by the Financial Conduct Authority,
are acting for GSK and for no one else in connection with the
Offering and will not be responsible to anyone other than GSK
for providing the protections afforded to their customers or
for affording advice in relation to the Offering, the contents
of this announcement or any transaction, arrangement or other
matter referred to in this announcement. Citigroup Global Markets
Limited and UBS Limited may participate in the Offering on a
proprietary basis.
This announcement does not represent the announcement of a definitive
agreement to proceed with the Offering and, accordingly, there
can be no certainty that the Offering will proceed. GSK reserves
the right not to proceed with the Offering or to vary the terms
of the Offering in any way.
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in Item 3.D
"Risk factors" in GSK's Annual Report on Form 20-F for 2014.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLIFIRVIIVLIE
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
Gsk (LSE:GSK)
Historical Stock Chart
From May 2023 to May 2024